product concentration

Depending on a few products for most revenue.

Exposure · 9 companies

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

  • ABBV AbbVie

    Exposed“Skyrizi and Rinvoq each generated more than 10% of 2025 total net revenues and together accounted for approximately **42%**.”

    Latest 10-QQ3 FY2026Positive ·

    Skyrizi and Rinvoq more than offset Humira erosion; lower acquired R&D and impairment charges amplify the earnings rebound.

    • Revenue$17.4BYoY +10.3%
    • Net income$4.2Bvs $186.0M year ago
  • GOOG Alphabet Inc.

    Exposed“Online advertising generated more than 70% of 2025 revenue, making Alphabet vulnerable to changes in advertiser spending, macroeconomic conditions, privacy rules, ad-blocking, and shifts in user behavior.”

    Latest 8-KDebt financing ·

    Closed a €6.0B euro-denominated senior note offering, adding fixed- and floating-rate debt with maturities through 2045.

  • LLY Eli Lilly and Company

    Exposed“Lilly’s revenue is highly concentrated in a small group of products: in 2025, Mounjaro, Zepbound, Verzenio, Trulicity, Taltz, and Jardiance (including Glyxambi, Synjardy, and Trijardy XR) each generated more than $3 billion in direct product and/or collaboration and other revenues and together represented 82% of total revenue.”

    Latest 10-QQ3 FY2026PositiveImpairment / charge ·

    Mounjaro and Zepbound volume growth outweighed lower prices, while acquired research charges constrained profit growth.

    • Revenue$24.4BYoY +38.6%
    • Net income$6.5BYoY +15.5%
  • MRK Merck & Co.

    Exposed“Keytruda represented 49% of FY2025 total sales.”

    Latest 8-KLeadership change ·

    Douglas M. Baker Jr. succeeds Thomas H. Glocer as independent lead director Jan. 1, 2027, ahead of Glocer’s May 2027 board retirement.

  • MRNA Moderna

    Exposed“Product concentration remains high in COVID vaccines.”

    Latest 8-KPositiveDebt financing ·

    Credit amendment cuts initial and delayed-draw term-loan margins 75 bp and extends maturity to November 2031.

  • PFE Pfizer

    Exposed“Pfizer’s sales are concentrated in a limited number of products: 12 products each generated more than $1 billion and together accounted for 65% of 2025 revenue; Eliquis alone represented 13%.”

    Latest 8-KCEO/CFO change ·

    Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.

  • RBLX Roblox Corporation

    Exposed“Content is also concentrated: 51% of in-experience hours engaged in December 2025 were in the top 50 experiences.”

    Latest 10-QQ3 FY2026MixedImpairment / chargeLegal / investigation ·

    Mandatory chat age checks slowed growth as fewer paying users weakened Robux bookings; earlier purchases sustained revenue.

    • Revenue$1.6BYoY +15.6%
    • Net income−$227.0MYoY +11.3%
  • TEL TE Connectivity

    Exposed“Approximately 38% of FY2026 net sales came from automotive customers, where downturns, customer work stoppages, sourcing changes, consolidation, and buyer price pressure can reduce demand and profitability.”

    Latest 10-KFY2026Positive ·

    AI data-center and grid demand made Industrial Solutions the largest operating-profit contributor, reducing reliance on automotive.

    • Revenue$19.9BYoY +15.2%
    • Net income$3.3BYoY +76.6%
  • VRTX Vertex Pharmaceuticals

    Exposed“Vertex remains highly dependent on CF revenue and faces clinical, regulatory, reimbursement, manufacturing and supply-chain risks, particularly for cell and gene therapies.”

    Latest 10-QQ3 FY2026Positive ·

    Crinetics adds an endocrine franchise, but deal costs and launch spending squeeze profit despite ALYFTREK-led sales growth.

    • Revenue$3.4BYoY +11.8%
    • Net income$653.6MYoY −39.6%

Feedback